Ductal Breast Cancer News and Research

RSS

Unraveling the role of HER2 mutant alleles in breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, "The uncharted role of HER2 mutant alleles in breast cancer."

6 Nov 2023

Multi-center analysis shines light on invasive lobular carcinoma

A multi-center analysis of patients with invasive lobular carcinoma, or ILC -; the second most common histological subtype of invasive breast cancer in the U.S. -; showed that, despite its prevalence, ILC is detected later and has worse outcomes than the predominant subtype of invasive breast cancer, known as invasive ductal carcinoma (IDC), or no special type.

14 Oct 2022

Study finds a more effective treatment option for HER2 mutant metastatic breast cancer

Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable.

23 Jun 2022

Single-dose radiation therapy may lessen, eliminate unsafe additional outside trips during the pandemic

According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases.

14 Dec 2020

Mutated gene GT198 has strong potential in early diagnosis of breast cancer

When mutated, a gene known for its ability to repair DNA, appears to instead cause breast cancer, scientists report.

21 Mar 2016

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

9 Dec 2015

MR-guided ultrasound may offer safe and effective treatment for breast cancer

A technique that uses focused ultrasound under magnetic resonance guidance to heat and destroy tumors may offer a safe and effective treatment for breast cancer, according to research being presented today at the annual meeting of the Radiological Society of North America.

4 Dec 2013

Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine, a JAMA Network publication.

6 Aug 2013

F-18-FDG PET/CT may easily predict disease-free survival for invasive ductal breast cancer patients

Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to research published in the September issue of The Journal of Nuclear Medicine. New data show that high maximum standard uptake value (SUVmax) of F-18-FDG in the lymph nodes prior to treatment could be an independent indicator of disease recurrence.

6 Sep 2012

Ductal Breast Cancer News and Research

Unraveling the role of HER2 mutant alleles in breast cancer

Multi-center analysis shines light on invasive lobular carcinoma

Study finds a more effective treatment option for HER2 mutant metastatic breast cancer

Single-dose radiation therapy may lessen, eliminate unsafe additional outside trips during the pandemic

Mutated gene GT198 has strong potential in early diagnosis of breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

MR-guided ultrasound may offer safe and effective treatment for breast cancer

Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

F-18-FDG PET/CT may easily predict disease-free survival for invasive ductal breast cancer patients

Genetic, lifestyle factors and HRT increase risk of breast cancer

Regular use of fish oil supplements reduces risk of invasive ductal breast cancer

Not all breast cancers' risk are increased by Hormone Replacement Therapy

Estrogen-progestin menopausal hormone therapy associated with high risk of both lobular and tubular breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News